04:30 PM EDT, 09/16/2024 (MT Newswires) -- I-Mab ( IMAB ) said Monday it has seen "encouraging" topline data from an ongoing phase 1 trial of givastomig in people with advanced cancers, especially gastric cancers.

The results were showcased at the congress of the European Society for Medical Oncology, or ESMO, which is taking place in Barcelona, Spain, the company said.

"Data presented at ESMO 2024 show that givastomig demonstrated continued monotherapy efficacy signals in heavily pre-treated patients, especially gastric cancers with a range of Claudin 18.2 expression levels and a strong overall safety profile," said I-Mab ( IMAB ) Chief Medical Officer Phillip Dennis.

The company's shares were rising nearly 4% in after-hours activity.

Price: 1.1000, Change: +0.04, Percent Change: +3.77